Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.99 USD | -0.14% |
|
-0.99% | +11.21% |
| 07-20 | Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026 | RE |
| 07-07 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 5,870 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 30.64% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 5,568 | 5,515 | 5,578 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 30.42% | -0.96% | 1.15% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -15.4x | -19.2x | -31.7x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 23.8x | 23.2x | 28.8x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 4.55x | 1x | 0.8x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 901x | 39.3x | 16.8x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 855x | 36.9x | 15.9x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -13x | -18.9x | -57.1x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -12.9x | -16.3x | -30.1x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -17.1x | -24.8x | -62.5x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.84% | -4.03% | -1.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.179 | -2.552 | -1.546 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 6.512 | 149.5 | 350.1 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -426.8 | -292.4 | -97.64 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -430.4 | -337.6 | -185.1 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -409.7 | -356.3 | -209.9 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -302.1 | -355.6 | -292.4 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 48.99 | 48.99 | 48.99 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 119,828 | - | - |
| Announcement Date | 3/7/22 A | 3/7/23 A | 3/19/24 A | 2/27/25 A | 3/3/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.41x | 855.11x | -13.05x | -.--% | 5.87B | |
| 20.76x | 6.35x | 13.89x | 1.53% | 55.23B | |
| 31.7x | 7.83x | 24.1x | 0.05% | 53.75B | |
| -18.35x | 4.4x | -7.71x | -.--% | 23.48B | |
| -39.73x | 12.6x | -37.13x | -.--% | 22B | |
| 24.86x | 4.85x | 12.85x | -.--% | 19.78B | |
| 24.09x | 4.69x | 15.26x | -.--% | 17.44B | |
| -736.67x | 34.86x | -3924.15x | -.--% | 14.66B | |
| 17.61x | 5.1x | 11.9x | -.--% | 14.07B | |
| 39.36x | 15.8x | 40.68x | 0.09% | 13.02B | |
| Average | -65.18x | 95.16x | -386.34x | 0.17% | 23.93B | |
| Weighted average by Cap. | -32.06x | 29.83x | -231.16x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
